LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today ...
New executive appointment made ahead of pivotal study results, potential regulatory approval and subsequent commercialization of investigational COMP360 psilocybin treatment Latest of several key ...
COMPASS Pathways focuses on developing COMP360 psilocybin for treatment-resistant depression, facing significant challenges due to its Schedule I status. Key risks include market acceptance, ...
LONDON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental ...
COMPASS Pathways plc CMPS, the London-headquartered psychedelics biotech company reported financial results for the third quarter 2023 ended September 30, showing: Cash and cash equivalents of $248.0 ...
We recently compiled a list of the 13 Best Psychedelic Stocks to Invest in Now. COMPASS Pathways Plc is one of them. COMPASS Pathways Plc (NASDAQ:CMPS), a biotechnology company specializing in ...
Asianet Newsable on MSN
Psychedelics break out of the fringe under RFK Jr’s 2025 reset — but did MNMD or CMPS own the year?
Regulatory thaw, political backing, and late-stage data are propelling psychedelic drugmakers into the biotech spotlight — ...
Newly created role of Chief Patient Officer reinforces Compass’ vision of working to achieve broad and equitable access to COMP360, if approved “Steve has spent the past four years working to deeply ...
LONDON, June 26, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback